Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU (NCT06116110)
A Prospective, Observational, Long-term Follow-up Study for Subjects Who Previously Received Zamtocabtagene Autoleucel in a North American Miltenyi Biomedicine-Sponsored Clinical Study
🩺 Plain-English Summary (8th-Grade Level)
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
- Long-term Follow-Up (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Stanford University — Stanford, California
- Yale University — New Haven, Connecticut
- Robert H Lurie Cancer Center — Chicago, Illinois
- University of Kansas Cancer Center — Westwood, Kansas
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
- Dana Farber Cancer Institute — Boston, Massachusetts
- Duke University Medical Center - Division of Hematologic Malignancies — Durham, North Carolina
- Oregon Health and Science University Knight Cancer Institute — Portland, Oregon
- UT Southwestern Medical Center — Dallas, Texas
- Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin
📞 Contact the Study Coordinator
Phone: (617) 218-0044
Email: clinicaltrials@miltenyi.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non Hodgkin Lymphoma
- Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) — Duarte, California
- Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma — Tucson, Arizona
- TmCD19-IL18 in CD19+ Cancers — Philadelphia, Pennsylvania
- Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma — Cincinnati, Ohio
- Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas — Iowa City, Iowa
- Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies — Cleveland, Ohio
Explore by condition: All Non Hodgkin Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.